What did @zashcare actually say?
This is essentially a teaser video, not a deep clinical dive. Dr. Ash introduces a week-long series on hormone optimization, starting with the female menstrual cycle, and hints at a live pellet insertion demo. He names "the follicular phase or the proliferator phase" and mentions doing "a lot of bio-identical hormone replacement therapy." That's the full substance of the medical content here. There are no dosing claims, no treatment promises, just a framing video.
Credit where it's due: he explicitly says men should understand female cycles too, and that women themselves often don't fully understand their own cycle. That's not wrong. Studies consistently show low menstrual health literacy across populations, including among women themselves (Armour et al., 2019, BMC Women's Health). The setup is reasonable. What matters is what comes next in the series.
Does the science back this up?
The foundational premise, that understanding the menstrual cycle is necessary before discussing hormone therapy, is scientifically sound. Bioidentical hormone replacement therapy (BHRT) using pellets is a real, practiced modality, though it sits in contested clinical territory. The claim that it's necessary for "men to understand" female cycles before pellet therapy makes clinical sense in the context of couple-based care or shared decision-making, but it's a bit of a stretch as a standalone justification.
The term "proliferator phase" is likely a verbal slip for "proliferative phase," which is the correct clinical term for the estrogen-dominant phase following menstruation where the endometrium thickens. The follicular phase and proliferative phase overlap but are not identical terms, the follicular phase refers to ovarian activity, the proliferative phase to uterine changes. Conflating them is a minor but real inaccuracy (Mihm et al., 2011, Reproduction). Not a crisis, but worth flagging.
What did they get wrong (or right)?
The terminology mix is the only concrete clinical error in this video. Calling it "the follicular phase or the proliferator phase" as interchangeable is imprecise. They describe parallel processes: one happening in the ovary, one in the uterus. A clinician teaching this should distinguish them, not use them as synonyms.
On the broader topic he's previewing, pellet-based BHRT is where things get clinically murky. Pellets are not FDA-approved as a delivery method for hormone therapy. The Endocrine Society and ACOG have both noted the lack of robust randomized controlled trial data supporting pellets over conventional forms of hormone therapy (Stuenkel et al., 2015, Journal of Clinical Endocrinology and Metabolism). That doesn't mean pellets are dangerous or ineffective, but it does mean a clinician promoting them heavily should be transparent about the evidence gap. We'll watch for that in future videos.
What he got right: the framing that education comes before treatment is clinically responsible messaging. More providers should lead with it.
What should you actually know?
If you're considering any form of hormone replacement therapy, including pellet-based BHRT, there are things worth knowing before you sit in that chair. Pellet therapy delivers a fixed dose subcutaneously, meaning you can't easily adjust or stop it if you have a bad reaction, unlike gels or patches. That's not a reason to avoid it, but it's a real pharmacokinetic consideration your provider should walk you through.
Bioidentical does not automatically mean safer. The term refers to molecular structure matching endogenous hormones, not to a safety profile. Compounded bioidentical hormones are not equivalent to FDA-approved hormone therapies in terms of quality control or clinical evidence, a point the FDA has made explicitly. If a provider presents them as risk-free alternatives to conventional HRT, that's a red flag.
The menstrual cycle education angle is genuinely valuable. Understanding your own cycle, including what the follicular, ovulatory, luteal, and menstrual phases do hormonally, helps you advocate for yourself in clinical settings and recognize when something is off. That part of Dr. Ash's message is worth your time.